skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

12 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Buyers and Sellers: How Corporate Transactions are Shaping the Big Pharma Landscape

Buyers and Sellers: How Corporate Transactions are Shaping the Big Pharma Landscape

Scrip has been scrutinizing significant M&A deals in the pharma industry in light of companies’ 2019 financial results. We bring you insights into the impact of major acquisitions and divestments by Big Pharma, and consider what it means for the future. 

Topic M A

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval

Article

John Thero insists company is focused on approval and launch, as interest in European rights grow.

Topic Cardiovascular M A

Biomedtracker: 開発中医薬品をFDA承認確率で評価

A Historic Decade of Deal Making

A Historic Decade of Deal Making

In preparation for the webinar, download your free infographic, a snapshot view of M&A’s biggest deals and major players and what their activities indicate for the year ahead.

Topic M A

Biomedtracker: 開発中医薬品をFDA承認確率で評価

A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more. 

Topic M A

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Quick Listen: Scrip's Five Must-Know Things

Scrip August Podcast

Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things.

Topic Coronavirus M A

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals

Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.

Topic us-election-2020 M A Legal Issues

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector. 

Topic Coronavirus M A

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

In Vivo Deal Making Article Pack

In Vivo Deal Making Article Pack

Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。